Chondroitin Sulfate and Glucosamine in Equine Osteoarthritis: Do They Really Make a Difference?

Osteoarthritis (OA) remains one of the most common causes of pain, lameness, and reduced performance in athletic horses. Once established, the disease can be difficult to manage, making prevention and early intervention critical components of equine practice^1,2. 

Among the numerous joint-support products available today, the combination of chondroitin sulfate (CS) and glucosamine (GlcN) continues to attract attention.  

But how effective are these nutraceuticals in horses with osteoarthritis? 

Why CS and GlcN Matter 

Chondroitin sulfate is a major component of articular cartilage and plays an essential role in maintaining joint structure and function. Glucosamine, an amino sugar naturally present in glycosaminoglycans, contributes to cartilage resilience, shock absorption, and extracellular matrix maintenance^1,3. 

Research suggests that together, CS and GlcN may exert a chondroprotective effect by^4,5: 

• Reducing pro-inflammatory cytokines and prostaglandins 

• Inhibiting cartilage-degrading enzymes 

• Decreasing oxidative damage 

• Stimulating glycosaminoglycan and type II collagen synthesis 

These actions may help slow the progression of OA while improving joint comfort and mobility. 

What Did the Study Show? 

Using an experimentally induced fetlock osteoarthritis model, researchers evaluated horses receiving an oral CS-GlcN combination and compared them with untreated controls¹. 

As expected, osteoarthritis developed in both groups, with increasing lameness, cartilage degradation, radiographic changes, and elevated biomarkers of joint damage over time. However, horses receiving CS and GlcN demonstrated several clinically relevant advantages¹. 

Improved Lameness and Mobility 

Treated horses consistently showed lower lameness scores and better movement dynamics than controls. These improvements were confirmed using objective motion-sensor analysis, suggesting that the benefits extended beyond subjective clinical assessment^1,3. 

The likely explanation is the anti-inflammatory action of CS and GlcN, which can suppress cytokines such as IL-1 and IL-6, reduce prostaglandin production, and modulate chronic pain pathways¹. 

Reduced Joint Inflammation 

One of the most interesting findings involved prostaglandin E2 (PGE2), a key inflammatory mediator associated with osteoarthritis. 

Control horses showed a marked rise in PGE2 following cartilage injury, whereas treated horses maintained considerably lower concentrations throughout the study. This suggests that CS and GlcN may help dampen the inflammatory cascade that drives OA progression⁴. 

Better Ultrasound Findings 

Ultrasonographic examinations revealed less synovitis, reduced vascularization, and lower osteochondral damage scores in treated horses. These findings support the notion that CS and GlcN may contribute to preserving joint integrity and reducing inflammatory changes within the joint¹. 

What About Cartilage Biomarkers? 

Interestingly, treatment did not significantly reduce CTX-II, a biomarker of type II collagen degradation. This may reflect the severity of the surgically induced cartilage injury, which could have overwhelmed the protective effects of oral supplementation¹. 

However, the absence of biomarker improvement does not negate the clinical benefits observed in lameness reduction, inflammatory control, and joint function. 

Practical Take-Home Message 

The findings reinforce the role of CS and GlcN as supportive tools in osteoarthritis management. While they may not completely halt cartilage degeneration, they appear capable of reducing inflammation, improving comfort, and helping preserve joint function. 

These nutraceuticals should not be viewed as standalone treatments, but as part of a comprehensive OA management strategy that includes appropriate exercise modification, farriery, weight management, and targeted medical therapies. 

Clinical Pearl 

Oral chondroitin sulfate and glucosamine may offer the greatest value as early-intervention or preventive support in performance horses at risk of osteoarthritis, helping maintain joint health before irreversible damage develops. 

References  

1. Yamada AL, do Prado Vendruscolo C, Marsiglia MF, Sotelo ED, Agreste FR, Seidel SR, Fülber J, Baccarin RY, da Silva LC. Effects of oral treatment with chondroitin sulfate and glucosamine in an experimental model of metacarpophalangeal osteoarthritis in horses. BMC veterinary research. 2022 Jun 9;18(1):215. https://link.springer.com/content/pdf/10.1186/s12917-022-03323-3.pdf  

2. McIlwraith CW, Kawcak CE, Frisbie DD, Little CB, Clegg PD, Peffers MJ, Karsdal MA, Ekman S, Laverty S, Slayden RA, Sandell LJ. Biomarkers for equine joint injury and osteoarthritis. Journal of Orthopaedic Research®. 2018 Mar;36(3):823-31. https://doi.org/10.1002/jor.23738  

3. Artuzi FE, Puricelli E, Baraldi CE, Quevedo AS, Ponzoni D. Reduction of osteoarthritis severity in the temporomandibular joint of rabbits treated with chondroitin sulfate and glucosamine. PloS one. 2020 Apr 15;15(4):e0231734. https://doi.org/10.1371/journal.pone.0231734  

4. Morita M, Yamada K, Date H, Hayakawa K, Sakurai H, Yamada H. Efficacy of chondroitin sulfate for painful knee osteoarthritis: a one-year, randomized, double-blind, multicenter clinical study in Japan. Biological and Pharmaceutical Bulletin. 2018 Feb 1;41(2):163-71. https://doi.org/10.1248/bpb.b17-00556  

5. Leatherwood JL, Gehl KL, Coverdale JA, Arnold CE, Dabareiner RA, Walter KN, Lamprecht ED. Influence of oral glucosamine supplementation in young horses challenged with intra-articular lipopolysaccharide. Journal of Animal Science. 2016 Aug 1;94(8):3294-302. https://doi.org/10.2527/jas.2016-0343